Post Hoc Analysis of Sustained MRD Negativity (GRIFFIN Trial) in TE NDMM Patients

(4:5)

What is sustained MRD negativity?

(2:)

The FORTE trial: the value of sustained MRD negativity

(2:46)

The value of sustained MRD negativity in MM

(1:21)

ST3GAL1 as a novel biomarker of lack of sustained MRD negativity in multiple myeloma

(8:47)

Sustained MRD negativity in multiple myeloma

(55)

Sustained MRD Negativity in Transplant Eligible Patients | Camila Guerrero, PhD | IMS 2023

(1:40)

Impact of sustained MRD negativity and CR after ide-cel in patients with multiple myeloma

(2:14)

The immune microenvironment predicts sustained MRD-negativity after D-KRd treatment for myeloma

(2:20)

Sustained MRD for treatment guidance in myeloma

(47)

Efficacy outcomes of patients with myeloma who achieved sustained MRD negativity in CARTITUDE-1

(2:57)

Sustained MRD negativity in MM with lenalidomide maintenance

(2:)

Evaluation of Sustained MRD Negativity w/ Daratumumab-Combination Regimens in Relapsed Refractory MM

(40:47)

If a myeloma patient has MRD-negative status, does that mean that patient is cured?

(4:1econd)

Curative Strategy for High-Risk Smoldering Myeloma: Post-Hoc Analysis of Sustained Undetectable MRD

(9:55)

If the MRD test is negative, is that always a good predictor of a longer remission?

(3:14)

MRD2STOP: Can multimodal MRD negativity guide discontinuation of maintenance treatment in myeloma?

(12:9)

IMWG Conference Series: Reporting from ASH 2022

(59:27)

Sustained MRD negativity for three years can guide discontinuation of LEN maintenance in myeloma

(2:31)

MRD Results from Cartitude-4 (Cilta-Cel vs SOC) in RRMM | Rakesh Popat | #ASH24

(3:6)